Belluscura PLC (GB:BELL) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Belluscura PLC has announced a joint venture with Separation Design Group and a major medical device company to develop oxygen-based wound care solutions, focusing on continuously diffused oxygen therapy. This collaboration positions Belluscura to capitalize on the growing $22.5 billion wound care market by leveraging its expertise in oxygen technology and the partner’s distribution capabilities. The initial clinical study is set to begin in early 2025 outside the U.S., marking a significant step in addressing hard-to-heal wounds.
For further insights into GB:BELL stock, check out TipRanks’ Stock Analysis page.
